Roivant Sciences Ltd. (Nasdaq: ROIV) announced today that it has
commenced an underwritten public offering of $150 million of common
shares. In addition, Roivant expects to grant the underwriters a
30-day option to purchase up to an additional $22.5 million of
common shares. All of the common shares are being offered by
Roivant. The proposed offering is subject to market conditions and
other factors, and there can be no assurance as to whether or when
the offering may be completed, or as to the actual size or terms of
the offering.
Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and
Company, LLC and Cantor Fitzgerald & Co. are acting as
bookrunning managers for the offering.
The common shares are being offered pursuant to a registration
statement on Form S-3 that was previously filed with the U.S.
Securities and Exchange Commission (the “SEC”) and was declared
effective on October 3, 2022. The offering will be made only by
means of a prospectus supplement and accompanying prospectus. A
preliminary prospectus supplement related to the offering will be
filed with the SEC and will be available free of charge by visiting
EDGAR on the SEC’s website at www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may be obtained,
when available, from Goldman Sachs & Co. LLC, Attn: Prospectus
Department, 200 West Street, New York, NY 10282, by telephone at
(866) 471-2526 or by email at prospectus-ny@ny.email.gs.com; SVB
Securities LLC, Attention: Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext.
6105, or by email at syndicate@svbsecurities.com; Cowen and
Company, LLC, 599 Lexington Avenue, New York, NY 10022, by
telephone at (833) 297-2926, or by email at
Prospectus_ECM@cowen.com; or Cantor Fitzgerald & Co.,
Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York,
NY 10022, or by e-mail at prospectus@cantor.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction. Any offers, solicitations or offers to buy,
or any sales of securities will be made in accordance with the
registration requirements of the Securities Act of 1933, as
amended.
About Roivant Sciences
Roivant's mission is to improve the delivery of healthcare to
patients by treating every inefficiency as an opportunity. Roivant
develops transformative medicines faster by building technologies
and developing talent in creative ways, leveraging the Roivant
platform to launch "Vants" – nimble and focused biopharmaceutical
and health technology companies.
Roivant Sciences Forward-Looking Statements
This press release contains forward-looking statements.
Statements in this press release may include statements that are
not historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
(the "Securities Act"), and Section 21E of the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), which are usually
identified by the use of words such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intends," "may,"
"might," "plan," "possible," "potential," "predict," "project,"
"should," "would" and variations of such words or similar
expressions. Such words may identify forward-looking statements,
but the absence of these words does not mean that a statement is
not forward-looking. We intend these forward-looking statements to
be covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to,
statements regarding the terms and completion of the proposed
public offering, our or our management team’s expectations, hopes,
beliefs, intentions or strategies regarding the future, and
statements that are not historical facts, including statements
about the clinical and therapeutic potential of our products and
product candidates, the availability and success of topline results
from our ongoing clinical trials and any commercial potential of
our products and product candidates. In addition, any statements
that refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements.
Although we believe that our plans, intentions, expectations and
strategies as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a number of risks, uncertainties and assumptions,
including, but not limited to, those risks set forth in the Risk
Factors section of our filings with the U.S. Securities and
Exchange Commission. Moreover, we operate in a very competitive and
rapidly changing environment in which new risks emerge from time to
time. These forward-looking statements are based upon the current
expectations and beliefs of our management as of the date of this
press release, and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as required by
applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
Investors
Roivant Investor Relationsir@roivant.com
Media
Stephanie LeeRoivant Sciencesstephanie.lee@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Aug 2023 to Aug 2024